Suresh Pattathil is the Managing Director & General Manager, Allergan India (an AbbVie company) and also the President of the OPPI (Organisation of Pharmaceutical Producers of India).  He is responsible for the commercial operations of AbbVie in India region which includes Sri Lanka, Bangladesh and Nepal.

With more than 30 years of experience in the pharmaceutical industry, Suresh has held several senior management positions in companies such as Pfizer, Schering Plough, MSD and Ferring. Most recently he was the Chief Executive Officer for Ferring Pharmaceuticals India with responsibility for Commercial operations, Research & Development center and setting up a pilot plant and manufacturing facility in Hyderabad.  He has a broad experience in both specialty as well as mass therapeutic areas and in launching global products successfully in India.   In his role as President of OPPI  he drives the advocacy efforts for the global pharmaceutical companies in India.

Some of the key initiatives Suresh has driven in his career are in the areas of market access, public market business, geographical expansion, customer trade channel strategy and building the marketing capability for Ferring in the APAC region. He has an excellent knowledge & understanding of the pharma market.

Suresh holds a MBA (Marketing) and a Bachelor’s Degree in Science.

Bhushan Akshikar has been appointed as VP & Managing Director of GSK  India effective 1st December 2022.

Bhushan Akshikar is a seasoned business leader with a successful track record of over 26 years across several geographies within the pharmaceutical industry. Bhushan joined GSK India in September 2011 to lead the specialty business and commercial excellence function. In 2014, he was appointed Head of the Mass Markets business. He was subsequently elevated as the Managing Director of the publicly listed entity of GSK in Nigeria, Africa in end– 2016. Apart from a strong business turn–around, he also built a high performing, resilient team. He then moved to Turkey in 2019 as the VML to drive strategic initiatives and launches in both private and tender segments in the Middle East, Russia CIS & Africa region. In December 2020 he returned to India as the Commercial Head of the General Medicines business and has led a cultural transformation journey delivering strong results reflected in the competitive performance of all flagship brands.

Before joining GSK, Bhushan spent 15 years with Janssen, Johnson & Johnson, in various roles leading both specialty and primary care business units in local and regional positions living in India, S. Korea and Belgium.

Bhushan is married and has two sons. He loves exploring different cultures, languages and cuisine with his family in his free time.

A seasoned general management professional, Anil has extensive experience in the Healthcare / Pharma / Life Sciences space having worked across MNCs, leading Indian companies and a start-up in Dubai.

After superannuating as Managing Director of Zydus Healthcare Ltd, Anil was engaged as Senior Advisor – Life Sciences at IQVIA Consulting and Information Services India Pvt. Ltd., and most recently as Operating Partner at Jashvik Capital – a mid-market Private Equity Fund focussed on Healthcare & Consumer sector.

He has also spearheaded operations in leading pharmaceutical companies such as Novartis India Ltd, GSK India and Globalpharma, Dubai.

He is a strategic collaborator who interfaces with Board of Directors and relevant stakeholders to position business growth and operational ingenuity. An influential leader, Anil has championed multi-million-dollar businesses and is proficient in unlocking company value by successfully executing growth strategies, institutionalizing controls, and enhancing productivity.

His proven skill sets in operations leadership, change management, team building, deal negotiations, regulatory compliance, strategy development and management consulting contributed towards market leading results. During his tenure, the pharmaceutical business of Novartis in India grew faster than the MNC pharma sector and Zydus Healthcare Ltd also improved its market share, besides improving EBIDTA margins by over 40%.

Anil has functioned on the boards of Zydus Healthcare Ltd., Bayer Zydus Pharma Private Ltd., Novartis Healthcare Private Ltd and Biochem Pharmaceutical Industries Ltd.

He has attended Senior Executive Programs at Harvard Business School, USA and IMD Business School, Switzerland.

Shreyas has more than two and a half decades of experience in Finance and Accounting. Shreyas leads the finance and administration function in OPPI overseeing the budget management, accounting, financial planning and analysis, and is also responsible for the smooth functioning of the Secretariat. Prior to OPPI, Shreyas has spent 21 years at Pfizer Ltd and has handled areas such as Financial Planning & Analysis, Budgeting, Forecasting, Long Range Planning, P&L Management, Pricing, Accounts Receivable & Cost Audit. A Cost Accountant from the Institute of Cost & Works Accountants of India (ICWAI), Shreyas started his career with Cadbury India Limited and has worked with Boehringer Mannheim Limited and Ciba Geigy Limited.

Suresh Pattathil is the Managing Director & General Manager, Allergan India (an AbbVie company) and also the President of the OPPI (Organisation of Pharmaceutical Producers of India).  He is responsible for the commercial operations of AbbVie in India region which includes Sri Lanka, Bangladesh and Nepal.

With more than 30 years of experience in the pharmaceutical industry, Suresh has held several senior management positions in companies such as Pfizer, Schering Plough, MSD and Ferring. Most recently he was the Chief Executive Officer for Ferring Pharmaceuticals India with responsibility for Commercial operations, Research & Development center and setting up a pilot plant and manufacturing facility in Hyderabad.  He has a broad experience in both specialty as well as mass therapeutic areas and in launching global products successfully in India.   In his role as President of OPPI  he drives the advocacy efforts for the global pharmaceutical companies in India.

Some of the key initiatives Suresh has driven in his career are in the areas of market access, public market business, geographical expansion, customer trade channel strategy and building the marketing capability for Ferring in the APAC region. He has an excellent knowledge & understanding of the pharma market.

Suresh holds a MBA (Marketing) and a Bachelor’s Degree in Science.

Sampada Gosavi joined Astellas in Jan 2023 and leads the India operations of Astellas Pharma, a global Top 20 pharmaceutical research company.

As a highly impactful business leader, Sampada has built and led high-performance teams that created many successful brands and profitable businesses. She has a wealth of experience in handling mass / specialty therapy areas and launching global innovator brands successfully in India. She has deep insights in the areas of Marketing, Sales, Market Access , Healthcare Affairs, Strategy & Pipeline. Prior to Astellas, Sampada has been associated with Abbott, Boehringer-Ingelheim, Ranbaxy & Unichem in key leadership roles

Sampada has won multiple accolades for her work in the industry and recognised among the Top 100 Leaders of 2022. She firmly believes in the power of diversity, equity and inclusion, leading by example.

Sampada has a Bachelor’s degree in Pharmaceutical Sciences and a post graduate in Pharma Management

Sanjeev is the Country President and Managing Director for AstraZeneca India.

Sanjeev has been with AstraZeneca for 19 years. Over time, he progressed through several positions in India, Indonesia, Asia Pacific and International region, based in Singapore and the UK.

Most recently he was Country President for AstraZeneca Malaysia, where he has been instrumental in transforming the business, to achieve double digit growth outpacing market. He played a critical role in supporting the government in combating the pandemic through AZ’s Covid-19 vaccine and LAAB, as well as leading Corporate Affairs strategy and sustainability initiatives.

Sanjeev also assumed roles as VP PhAMA – an industry association, a Board of Director for the British Malaysia Chamber of Commerce and actively chairs Malaysia Cancer Care Coalition.

Sanjeev is a Science graduate with Post Graduation (MBA) and holds a Doctorate in Business Administration (PhD). He also holds professional Diplomas in International Business and HRM.

Shweta was appointed Managing Director of Bayer Zydus Pharma, and Country Division Head of the Pharmaceutical Division in South Asia, on 1st January 2024. She has been with the organization since 2019 and her last role was Business Unit Head for Diabetes Care.

With a distinguished career spanning over 22 years, Shweta has a strong track record of leading high performance diverse teams across strategic business positions in the pharmaceuticals and medical device sectors. Her expertise extends across a myriad of therapy areas, including Cardiology, Diabetes,
Women’s Health Care, Immunology, Virology, Anti-infectives, Vaccines, Neurology, Orthopedics and Pain Management. Prior to this, she worked with companies of repute like Johnson & Johnson, MSD Pharmaceuticals, IQVIA and Pfizer.

Shweta has been widely celebrated in the industry -she has been featured in “A List” India, a testament to her influence as one of the top 500 marketing influencers in the country. She has been acknowledged among the Top Women Leaders in the Health Care Industry by OPPI (Organization of
Pharmaceutical Producers of India); THE HINDU recognized her as one of the “India Businesswomen Leaders Below 40”. In 2019, she also received the prestigious “SIESCOMS Women Achiever Award” on International Women’s Day.

Shweta’s distinguished career is characterized by a strategic approach, a focus on innovation, and a commitment to excellence, making her a key figure in the healthcare industry.

Gagandeep Singh Bedi is the Managing Director and Head of Human Pharma of Boehringer Ingelheim India. He is also a member of the board of directors for India.

Gagan has an experience of over two decades in leading corporate strategy and fostering a customerfocused culture in multinational companies across geographies. Having worked across complex healthcare ecosystems, he is a strong advocate of driving patient benefit through innovative medicines
and sustainable care.

He is passionate about unlocking the potential of emerging technologies and leveraging innovation to become more patient-centric and improve community health outcomes.

Gagan started his career in pharmaceutical sales, building leadership across therapeutic areas such as diabetes, cardiovascular, oncology, and respiratory care. Gagan has lead enterprise-wide transformations through a shared purpose and cross-functional approach to talent development. As
a business leader, he has championed digital adoption through industry association and government partnerships.

Before joining Boehringer Ingelheim India, Gagan served as Head of Africa Cluster at AstraZeneca. Earlier in his career, he also worked with Eli Lilly, and Baxter.

Gagan is an Economics (Honours) graduate from Delhi University. An avid biker, he enjoys exploring the rustic terrains of India

Sanjay joined Bristol Myers Squibb (BMS) India in May 2022. He is an experienced leader with over eighteen years of experience in the healthcare and pharmaceutical industries in both India and international markets (UK, Australia and Japan).

His extensive experience encompasses strategy, business planning, general management, P&L management, sales, marketing, launch excellence, market access, and sales force excellence.
Prior to joining BMS India, Sanjay was the Managing Director at Astellas India, where he led the company’s country operations. He has also held various commercial leadership roles with leading healthcare and consulting organizations, including Johnson & Johnson, MSD, Dr. Reddy’s Laboratories and Ernst & Young.

Sanjay holds a Chemical Engineering Bachelor from Indian Institute of Technology (IIT), Bombay and an MBA degree from the Indian School of Business (ISB), Hyderabad.

Outside of work, Sanjay is a dedicated marathoner and enjoys reading and exploring world history and mythology.

Sanjay is married to Shikha and they have a daughter, Omesha.

Vineet Gupta, Managing Director, Eli Lilly & Company – India & India Subcontinent was appointed to his current role in January 2022.

Vineet joined Lilly in 2010 as Marketing Director for India and later moved to the Corporate Affairs & PRA Director role in 2012. Over the years he has held diverse leadership positions across the globe including General Manger for Thailand, Philippines & Indonesia. In his previous role before moving to India, Vineet held the strategic position of Go-to-Market Lead for Anti-COVID Therapies for International Markets based at Lilly Corporate HQ, Indianapolis, US. Vineet spent 8 years with Johnson & Johnson Medical in various sales & marketing roles prior to joining Lilly.

Vineet holds a Bachelor of Technology degree from the prestigious Indian Institute of Technology (IIT) Delhi in 1999 and later completed his MBA from Indian Institute of Management (IIM) Calcutta in 2002.

Vineet’s vision for India is to build on Lilly’s legacy of making life better for patients through the innovative portfolio of Lilly and expand our patient reach in India & the subcontinent. Another crucial priority for him is to drive a diverse & inclusive culture and make Lilly an employer of choice in India.

Sudheendra is an accomplished leader in Pharmaceutical Industry with more than two decades of experience across leading multinational and Indian corporations in India and South Asian region.

As CEO of integrated Ferring Pharmaceuticals operations, Sudheendra leads commercial operations, guides R&D and manufacturing operations for India and South Asian countries. He is part of APAC leadership team actively contributing to collaborate across the AP region.

Prior to the current role, he served in senior and increasing leadership roles across MSD, J&J, Ranbaxy and GSK, including managing country commercial operations for MSD India in second half of 2019 during the leadership transition. In prior roles he lead the entire specialty care business at Janssen Pharmaceuticals, successfully managed the alliance of Ranbaxy & Sanofi Pasture for access of vaccines in India in 2004. His passion is in areas of Building coalitions, D&I, Strategy and Market Access for serving patients in this part of the world. He has been an active contributor to OPPI marketing and Access committees since 2010.

Outside of work Sudheendra is passionate about Indian Classical Music, and an ardent follower of Capital markets around the world. He holds a Bachelor’s in Chemistry and Master of Business Administration (MBA) from Karnataka University.

Bhushan Akshikar has been appointed as VP & Managing Director of GSK  India effective 1st December 2022.

Bhushan Akshikar is a seasoned business leader with a successful track record of over 26 years across several geographies within the pharmaceutical industry. Bhushan joined GSK India in September 2011 to lead the specialty business and commercial excellence function. In 2014, he was appointed Head of the Mass Markets business. He was subsequently elevated as the Managing Director of the publicly listed entity of GSK in Nigeria, Africa in end– 2016. Apart from a strong business turn–around, he also built a high performing, resilient team. He then moved to Turkey in 2019 as the VML to drive strategic initiatives and launches in both private and tender segments in the Middle East, Russia CIS & Africa region. In December 2020 he returned to India as the Commercial Head of the General Medicines business and has led a cultural transformation journey delivering strong results reflected in the competitive performance of all flagship brands.

Before joining GSK, Bhushan spent 15 years with Janssen, Johnson & Johnson, in various roles leading both specialty and primary care business units in local and regional positions living in India, S. Korea and Belgium.

Bhushan is married and has two sons. He loves exploring different cultures, languages and cuisine with his family in his free time.

Jayashri is a strong business leader with over 25 years of diverse and multi-segment (Pharmaceuticals, Healthcare Consulting and Medical Devices) experience in healthcare across India and Asia Pacific in various roles ranging from Sales, Corporate Strategy, Consulting, M&A and Business Development, Insights & Analytics and, most recently, Commercial/Business Leadership. She brings solid hands-on learning experience and success in the commercialization of new innovative business ventures. Her extensive background includes navigating the complexities of healthcare delivery, developing effective go-to-market models and successfully launching groundbreaking products and services.

She completed her postgraduation in Management from S. P. Jain Institute of Management and Research, Mumbai and holds a bachelor’s degree in Pharmaceutical Sciences from the Institute of Chemical Technology (ICT), Mumbai.

Pratima has an extensive experience of over 17 years, with nine years in the pharmaceutical industry, including varied roles across functions in national and global teams since joining Merck in October 2013, including strategy consulting, project management, driving speciality business in healthcare.

In the capacity of Director, Portfolio Management & R&D Strategy – Consumer Healthcare Business, Pratima was part of the Global R&D LT driving set-up and delivery of the innovation projects portfolio in-line with the division’s growth aspirations. In this role she effectively managed monthly Innovation Management Board (IMB) chaired by the CEO for Gate Decisions, Funding Decisions, Innovation portfolio prioritization/review and led key programs for the CEO’s office.

Pratima has headed the Oncology Unit at Merck India Healthcare Business where she led the turnaround of the Oncology business by demonstrating the opportunity to drive strong growth via focused access strategies.

Prior to taking over as the Managing Director of India Operations, Pratima was the Regional Franchise Leader (RFL) of the Cardiovascular, Metabolism and Endocrinology (CM&E) franchise in APAC. An active member of the APAC Leadership team, her efforts have ensured that the CM&E franchise continues to grow in the region and continues its market leadership despite market challenges.

Prior to Merck, Pratima worked with Accenture for 8 years leading cross-functional management and risk assessment projects, among others.

Pratima holds a Masters’ degree in Accountancy from Mumbai university and an MBA from Jamnalal Bajaj Institute of Management Studies, India.
Pratima is an outcome-oriented leader with demonstrated ability to work across cultures, and business areas, and focuses on creating positive impact across the organisation.

Rehan A. Khan joined MSD in India in January 2020 as Managing Director, India Region. He is responsible for driving MSD’s business in India, in-line with the company’s vision of providing patients access to critical therapies.

Rehan is an accomplished international leader with over 20 years of experience in leading large multinational companies across various markets including India, South Asia, Greater China, Southeast Asia and across Asia Pacific. He has been the President Asia Pacific of DaVita, a NYSE-listed dialysis services provider with presence across 50 cities in Asia. Earlier, Rehan was the MD and Executive Director of Abbott India Ltd, a publicly listed Pharma company. Prior to relocating to Asia, Rehan spent over a decade across Europe and in the US with Novartis, Accenture and with Venture Media LLP.

More recently, Rehan was an entrepreneur and founder of First Penguin Capital, a Dubai & Singapore based early stage fund focused on investing in health and consumer tech startups. He has also been an advisor to and board member of several healthcare companies and private equity funds across Asia and Africa.

Rehan is an alumnus of the Advanced Management Program at Harvard Business School and graduated with an MS in Health Sciences from the Harvard-MIT Division of Health Sciences – a joint program between Harvard Medical School and MIT. He has an MBA from Drexel University and a BS from the University of Wisconsin.

Amitabh is recently appointed as the Country President for Novartis In India. Prior to this Amitabh was the Country President for Novartis Vietnam and was also the General Manager for Novartis Oncology for Vietnam. He was the Chairman of the Local Industry Forum in Vietnam – Pharma Group and was also the Board member of the same. In last 2-year Amitabh has played a significant role in leading on Policy matters for the Industry in Vietnam

Prior to this role Amitabh was the General Manager Novartis Oncology India and was heading business operations for India, Srilanka, Nepal and Maldives. Along with this, he has additional responsibility as Head of Marketing and Commercial Excellence for Asia Cluster. Amitabh has more than 28 years of experience in pharma industry, with consistent track record of achieving business results and has led various business functions. For last 14 years, he has worked in General Management and has been part of various leadership teams.

Before joining Novartis, Amitabh worked with Roche a leading Swiss pharma company as the Business Director of Oncology Business Unit and has been responsible for launching some blockbuster molecules in India. In his tenure of 12 years with Roche, he has lead successfully functions of corporate affairs, business operations, marketing and sales. He started his career in pharmaceutical industry as front-line sales role with Nicholas Piramal India Limited. Amitabh is well versed with various aspects of the pharmaceutical market in India including the corporate affairs, regulatory & IP environment, pricing, sales, strategic marketing, business development, distribution and supply chain. Amitabh Is extremely Passionate about Healthcare strengthening and focus on improving the Quality care for Patients . He is also very Focused on developing and promoting talents in Pharmaceutical & Healthcare space

Amitabh has been an active member and part of various industry associations. He holds a Master’s degree in Bio Chemistry and has been part of business executive programs of Insead University France, Tuck Business School University Dartmouth (US), and Columbia Business School (US).

Vikrant Shrotriya is Managing Director & Corporate Vice President for Novo Nordisk’s India business. He is based in Bengaluru.

Vikrant has a distinguished career spanning over 20 years in the healthcare industry, in India and internationally. He has studied at Delhi University and Symbiosis Institute of International Business (SIIB), Pune and has worked in many national and international organisations in India, South East Asia and more recently in the GCC (Gulf Cooperation Council) countries where he was Vice-President for Novo Nordisk’s GCC business and Corporate Vice President for Saudi Arabia.

Vikrant has been honoured with several accolades throughout his career. Most recently, he received one of the highest awards from the Danish Government – “His Royal Highness Prince Henrik’s Medal of Excellence” – in recognition for his outstanding contribution to business and trade.

Parag Swadia is the CEO of Otsuka Pharmaceutical India Private Limited – OPI. With 25 years of professional experience, including 10 years at Otsuka, he has established himself as a leader in the industry.
His journey within the company began in 2013 when he assumed the role of Head of Finance & Accounts, eventually progressing to Head of Corporate Planning in 2016, and then Vice President of Corporate in 2018. His responsibilities encompassed various crucial aspects of the business, including International Business spanning 60 countries, Supply Chain management, Human Resources, Information Technology, Legal & Secretarial matters, and Corporate Affairs. In 2019, he became a Director and a Board Member, before finally being appointed as the CEO in 2024.
Prior to his tenure at Otsuka, Parag Swadia worked with Essar group companies for a decade mainly focusing on the domain of finance and accounts. He had started his career working with esteemed Cost Accountant and Chartered Accountant firms in India which provided exposure into various industries audit & consultancy work. His experience in these areas equipped him with a comprehensive understanding of financial functions, including Management Information Systems (MIS). Upon joining OPI, he was able to leverage his expertise to contribute significantly to the company’s growth and success. OPI, under his leadership, has emerged as a key player in the pharmaceutical industry, particularly in the production of IV fluids. With revenues exceeding Rs. 600 Crore and a workforce of around 2000 employees, OPI has established itself as a vital part of Otsuka Holdings Co., Ltd. Parag Swadia’s commitment to delivering innovative, high-quality products aligns with Otsuka’s global vision, making him a respected figure in the organization as the CEO and Executive Director.
Outside of work, Parag enjoys various hobbies such as listening to all types of music, chanting in Sanskrit, exploring new places through travel, and engaging in “gau seva” or service to cows. He values the concept of “vasudhaiva kutumbakam,” which emphasizes the idea that the world is one family.

Meenakshi Nevatia is the Country President & Managing Director for Pfizer India effective April 3, 2023

Prior to joining Pfizer, Meenakshi has been the Managing Director for Stryker India. Stryker is a leading Medical Technology business. Meenakshi was responsible for building Stryker’s business strategy and setting up the organization for long-term, sustainable growth in the Indian market. Additionally, one of Meenakshi’s priorities was to build a winning culture and cultivate a strong commitment to Stryker’s mission and values in India. Meenakshi was on the Board of the Medical Technology Association of India (MTAI), in the Governing Council of Nathealth and CII (Confederation of Indian Industry) and was the C0-Chair of the Med Tech Committee at AMCHAM (American Chamber of Commerce).

Prior to joining Stryker, Meenakshi had a successful 15-year stint with Novartis, where she served in various sales, marketing and business leadership positions across geographies. In her last assignment as the country president and pharma division head for Novartis in Thailand, Meenakshi successfully led strong business performance. Prior to these roles, Meenakshi had a successful track record of serving in various leadership positions in country, region and global at Novartis across Spain, Portugal, UK, Switzerland & Hong Kong.

Meenakshi started her career with McKinsey & Company where she led various projects in the Healthcare Practice (Pharmaceuticals, Medical Devices & Health Insurance) across several markets including India, Singapore, U.S. and South Africa.

Meenakshi has a Master of Business Administration in Strategy and Finance from the Indian Institute of Management, Ahmedabad (IIM A), and Bachelor of Science in Economics and Mathematics from the Presidency College, Kolkata.

Simpson oversees India affiliate’s operations and provides guidance towards achieving the company’s North Star of Delivering Better Outcomes for More Patients, Faster.   

Simpson has nearly 20 years of experience in the Indian pharmaceutical sector, especially in areas of marketing, strategic planning, sales management, new product planning and patient access programs. He joined Roche in September 2014 and since then he has led various functions and teams at a national as well as global level. 

He holds a Master’s degree in Health Economics (Economic evaluation and health technology assessments) from the University of York, UK, a Post-graduate Diploma in Business Administration in Marketing & Systems and a Bachelor’s degree in Physics.

Rodolfo Hrosz is the Country Lead and Managing Director of Sanofi India Limited. Present in India since 1956, Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives.

Hrosz joined Sanofi as General Manager of the Consumer Healthcare business in Brazil in 2017. He brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies.

His diverse global experiences, particularly in key emerging markets, are assets that will hugely benefit the company’s development.

Prior to joining Sanofi, he has worked with Pfizer, LVMH, Heineken and Procter & Gamble in USA and in Brazil.

An MBA from the University of Pittsburgh, Hrosz is also qualified as a naval engineer and in finance and accounting.

Pierre is a Pharma Executive with over 25 years of experience in Sales, Marketing, country and region management and P&L within the Pharmaceutical industry – in Europe, North and South Africa, Near and Middle East Region and Asia.

After different positions for multinational Pharma companies, Pierre is currently the CEO of SERDIA Pharmaceuticals (India) Pvt. Ltd. (an affiliate of the SERVIER group, a French multinational company with more than 22,000 employees worldwide). He leads a team of 500+ collaborators in India and is responsible for steering and promoting all the activities of SERDIA in INDIA.

His experience includes markets, regional and global roles, both in launching therapeutic innovations in different therapeutic areas, optimizing life-cycles of brands and opening & developing new markets. He has forged strong relationships with local health authorities, leaders and professional organizations.

His expertise lies in Cardiovascular, CNS, Diabetes, HIV, Oncology therapeutic fields, as well as management, marketing strategy, sales management, product launches, project management, regulatory, finance, market access, people development and leadership.

Hobbies and interests include – Sports, Music and Travel.

Serina Fischer was appointed the General Manager for Takeda in India in March 2022. Serina has over 17 years of progressive experience in the Biopharmaceutical industry and is an accomplished, dynamic leader with experience in designing strategy, building capabilities, tracking execution, and delivering customer value. She has held several roles in sales, marketing, and operations.

Driven by innovation and a passion to serve patients, Serina believes that performance driven leadership and dynamic capability are instrumental to driving growth for the organisation and her team. In her current role, Serina will lead the company’s business in India, ensuring patient access to the company’s highly innovative medicines.

Serina joined Takeda in 2017 and has held various leadership roles in its US affiliate. She assumed various  roles at Eli Lilly and company, Independent Capital Management and Citadel Law Corporation before  joining Takeda. 

Serina earned a bachelor’s degree in Applied Science (B.A.Sc.), Sociology- Human Development from  California State University, Long Beach logo and is a certified Six Sigma Black Belt.